The epidemiology of hepatocellular carcinoma (HCC) is characterized by dynamic temporal
trends, several major established (ie, HCV, HBV, alcohol) and emerging (ie, diabetes …

Metformin as a first-line drug for type 2 diabetes mellitus (T2DM) treatment is widely studied.
Metformin can reduce liver glucose output and improve insulin resistance. Recent evidence …

Background & Aims Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
(NAFLD/NASH) is an increasing clinical problem associated with progression to …

Hepatocellular carcinoma (HCC) is one of the most lethal cancers, and its rate of incidence
is rising annually. Despite the progress in diagnosis and treatment, the overall prognoses of …

Tremendous efforts have been made to elucidate the basis of cancer biology with the aim of
promoting anticancer drug development. Especially over the past 20 years, anticancer drug …

Overexpression of hypoxia-induced factor 1α (HIF-1α) has been shown to be involved in the
development and progression of hepatocellular carcinoma (HCC). HIF-1α should therefore …

Background & Aims CD26, a multifunctional transmembrane glycoprotein, is expressed in
various cancers and functions as dipeptidyl peptidase 4 (DPP4). We investigated whether …

Meta-analysis of studies using metformin as a reducer for li... : Medicine Meta-analysis of studies
using metformin as a reducer for liver cancer risk in diabetic patients : Medicine Log in or …

Background & Aims Type II diabetes mellitus worsens the prognosis of cirrhosis. Multiple
medications including metformin and statins often are co-administered to manage patients …

During the last decade, the burst of interest is observed to antidiabetic biguanide metformin
as candidate drug for cancer chemoprevention. The analysis of the available data have …